Top 5 Growth Stocks in Biotech

Page 5 of 5

1. Orchard Therapeutics plc (NASDAQ:ORTX)

Revenue Growth YOY: 1255.03%

Headquartered in London, United Kingdom, Orchard Therapeutics plc (NASDAQ:ORTX) is a biopharmaceutical company that develops gene therapies for severe life-threatening rare disorders. The company’s therapeutic approach seems to utilize the hematopoietic stem cells (HSCs) in the human body to permanently address the underlying factors of a genetic disorder through a single administration. The product pipeline of Orchard Therapeutics plc (NASDAQ:ORTX) consists of several products for the treatment of various neurodegenerative and immunological disorders.

On March 6, 2023, Orchard Therapeutics plc (NASDAQ:ORTX) announced its fourth quarter 2022 results. The company’s revenue stood at $6.99 million, surpassing wall street estimates by $1.67 million. The Normalized EPS was reported to be $0.06, beating market expectations by $0.15.

As per Insider Monkey’s database, 7 hedge funds held stakes worth $3.6 million in Orchard Therapeutics plc (NASDAQ:ORTX) in Q4 2022, compared to 8 funds in the prior quarter with stakes worth $7.8 million.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a look at 11 Most Promising Car Stocks to Buy and 11 Best Coal Mining Stocks to Buy Today.

Follow Insider Monkey on Twitter

Page 5 of 5